^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + eganelisib (IPI-549) (PI3Kγ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Infinity Receives Fast Track Designation for IPI-549 in Combination with the Checkpoint Inhibitor Opdivo for the Treatment of Advanced Urothelial Cancer
Published date:
03/25/2020
Excerpt:
...the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IPI-549 in combination with nivolumab (Opdivo®) for the treatment of advanced urothelial cancer.
